Indianapolis ‘Top Docs’ James Donahue, MD & Leo Bonaventura, MD, Welcome First Twin INVOcell Babies in the State of Indiana
MEDFORD, Mass., Nov. 8, 2018 — INVO Bioscience, Inc. (OTC: IVOB), a medical device company granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced Family Beginnings, PC, a leading reproductive medicine practice in Indianapolis, reported the first delivery of healthy babies in the State of Indianautilizing the INVOcell technology. Family Beginnings, PC is operated by two of the leading advocates of the INVOcell fertility process – James Donahue, MD & Leo Bonaventura, MD, who were again recently named ‘Top Docs’ by Indianapolis Monthly magazine, as they have in previous years.
Katie Karloff, chief executive officer of INVO Bioscience, said, “We are delighted by the news of Indiana’s first INVOcell babies. Drs. Donahue and Bonaventura early on recognized the potential of INVOcell to safely enable pregnancies in couples that were not successful utilizing traditional in-vitro fertilization therapies. They also recognized the cost-effective nature of the INVOcell process to create the families that so many in the Indianapolis community desire. With more than 50 years of experience helping couples build their families, we are proud to be working with Family Beginnings.”
INVOcell is a patented medical device used in the treatment of infertility that enables egg fertilization and early embryo development to take place in the woman’s body, in vivo. The INVO Solution allows women to incubate their own gametes, providing a psychological benefit while reducing the risk of wrong embryo transfer. Utilizing a mild stimulation protocol, it decreases the number of oocytes required, which may reduce the risk of severe ovarian hyperstimulation (OHSS), reduce the risk of multiple births, and/or reduce the need for embryo cryopreservation and storage. As a lower cost option to traditional IVF, INVOcell expands access to patients who may otherwise be unable to afford the traditional method or would prefer for a more natural, cultural, or religious appropriate choice.
About Family Beginnings
We are one of the oldest fertility practices in Central Indiana. Our two doctors have over 50 years of experience helping couples build their families. Dr. Leo Bonaventura and Dr. James Donahue have both been named ‘Top Docs’ in the Indianapolis Monthly Magazine multiple years running. Our best-in-class ART laboratory is certified by the American College of Pathology and we are Members of the Society of Assisted Reproductive Technology for over 17 years. We are committed to providing the most advanced reproductive care available. We think that INVOcell will help more patients utilize fertility treatments. For more information, please visit www.invocellindiana.com.
About INVO Bioscience
We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit https://invobioscience.com/.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Kathleen Karloff, CEO
INVO Bioscience, Inc.
978-878-9505 ext. 504